Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
about
New Antiretroviral Treatment for HIVKidney Disease and HIV Infection.Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed AdultsLack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with PreserveAntiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA PanelThe efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis.Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected AdultsEquivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in EuropeRilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.Tenofovir Alafenamide.Emtricitabine + tenofovir alafenamide for the treatment of HIV.Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.Kidney Disease in HIV: Moving beyond HIV-Associated Nephropathy.Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects.Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a rAntiretroviral treatment for HIV infection: Swedish recommendations 2016.How can we achieve universal access to low-cost treatment for HIV?Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug.Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens.Bone and the Immune System.Plasma and Intracellular Pharmacokinetics of Tenofovir in Patients Switched from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide.Adipocytes impair efficacy of antiretroviral therapy.Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction.Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority TrialDarunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
P2860
Q28069829-D6F5BFCD-2376-4344-93D2-65C1AEA36943Q30234837-60253854-DA2E-42A0-8E4C-EE70292A7916Q33669829-CA912C79-01F3-4A88-8CEC-6B143F2CECD8Q36284159-76F018AD-02F0-45C0-AC16-1FEC26D0F7D9Q36541070-A7C59459-87C8-4182-BCC0-5E4BB9F96599Q37141511-ACC423C9-B3DD-4C56-BD6F-71C2F4F6E6CEQ37234729-F0AF96BB-38DD-4230-B134-023090284B98Q37354871-EE701240-ED12-41C1-8451-79033384B207Q37582471-083E3CD5-AC74-4781-B3D9-9D6057021B2BQ37582474-9FDD8991-2879-41CD-91BC-354C41EFED1DQ37604553-2C240AAF-0B5C-45C7-BF81-B348B92D531EQ37631931-7A3CD614-3D8F-41ED-B66A-E1C9B97E0D09Q38802093-E49DFCEA-BC68-4608-B32B-40A1A87FBD52Q38836878-0CF1B5FF-5032-4868-A074-A3DDA90F5A17Q38910661-1CB0B4A9-4372-4602-8BA5-D7039B306D54Q38984695-86E4E29B-0EAE-484A-B516-2715799945FCQ39002230-7C3161BF-B36E-4373-A465-40183FAD88F6Q40103229-F7603CEF-8158-4620-A836-65B68DAAE96CQ40127599-AC7EA59F-A76B-4882-9E90-A3E371055E9AQ40185119-E63A4B81-0E1A-4300-A01D-49BF2A62522CQ40288176-A5B1B819-968B-43F1-8A8D-4B4FC8B46577Q40470257-103FF9F8-10C1-434C-86CC-43A323405887Q42380889-B5621602-0A41-4F30-9E74-F35EA899AEF4Q45961010-9522B19A-134D-4C11-A853-94BE5BDBA538Q47560453-ED5BFB44-0418-495D-9E38-7AC766889DA7Q47562735-D0953C0E-5A80-4D2A-B168-6985D5624965Q47608253-A30B6C24-666B-4BF1-8609-B7ED8C2E8151Q48506430-9B1EE119-F3B1-4970-B979-22039A2FFF0FQ52720640-9F4248C9-EE45-4B52-AB0C-284674F4E637Q54230654-D2146BE4-164D-4875-A6D5-6CF8749065CFQ55475404-CB22212A-EAD8-4823-95FF-5D533A23EEF6Q56988548-AE405D00-C74A-4287-9F1E-6F73D57097AFQ59126145-FE97FD8F-30E4-4703-96FE-3256FD6A5058
P2860
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Brief Report: A Randomized, Do ...... -1 Treatment: Week 96 Results.
@en
Brief Report: A Randomized, Do ...... -1 Treatment: Week 96 Results.
@nl
type
label
Brief Report: A Randomized, Do ...... -1 Treatment: Week 96 Results.
@en
Brief Report: A Randomized, Do ...... -1 Treatment: Week 96 Results.
@nl
prefLabel
Brief Report: A Randomized, Do ...... -1 Treatment: Week 96 Results.
@en
Brief Report: A Randomized, Do ...... -1 Treatment: Week 96 Results.
@nl
P2093
P1476
Brief Report: A Randomized, Do ...... -1 Treatment: Week 96 Results.
@en
P2093
Amanda Clarke
Andrew Cheng
Antoine Cheret
Bruce Rashbaum
Christian Callebaut
Cristina Mussini
Cynthia Brinson
David Wohl
GS-US-2,92-01040111 and Study Team
Jason Brunetta
P356
10.1097/QAI.0000000000000940
P407
P577
2016-01-29T00:00:00Z